Skip to main content

Table 3 Loss of heterozygosity in different tumours

From: The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors

Type of cancer

Heterozygous patients (%)

Patients with LOH (%)

HER2-positive

33/85 (39)

16/33 (48)

HER2-negative

22/52 (42)

2/22 (9)

Cervical cancer

26/65 (40)

11/26 (42)

Lung cancer (ā™€)

6/18 (33)

4/6 (67)

  1. LOH, loss of heterozygosity.